Redefining extended-spectrum beta-lactamases: balancing science and clinical need.

@article{Giske2009RedefiningEB,
  title={Redefining extended-spectrum beta-lactamases: balancing science and clinical need.},
  author={Christian G. Giske and Arnfinn S Sundsfjord and Gunnar Kahlmeter and Neil Woodford and Patrice L. Nordmann and David L Paterson and Rafael Cant{\'o}n and Timothy R. Walsh},
  journal={The Journal of antimicrobial chemotherapy},
  year={2009},
  volume={63 1},
  pages={1-4}
}
The current beta-lactamase classifications have reached a high level of complexity, making them less accessible to clinicians, infection control professionals, hospital management and politicians. From the clinical perspective, a revised comprehensible nomenclature scheme is therefore needed. The term extended-spectrum beta-lactamases (ESBLs) has reached a broader audience over time, but is currently restricted to functional class 2be/molecular class A, clavulanic acid inhibited enzymes with… CONTINUE READING